Compare LTRX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRX | TARA |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.5M | 236.1M |
| IPO Year | 2000 | 2014 |
| Metric | LTRX | TARA |
|---|---|---|
| Price | $5.20 | $3.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.50 | ★ $24.40 |
| AVG Volume (30 Days) | ★ 1.1M | 324.4K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.52 | 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,899,000.00 | $2,948,000.00 |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $15.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.37 | $3.02 |
| 52 Week High | $8.75 | $7.82 |
| Indicator | LTRX | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 39.12 |
| Support Level | $5.08 | $3.73 |
| Resistance Level | $6.86 | $4.17 |
| Average True Range (ATR) | 0.36 | 0.14 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 2.08 | 17.91 |
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The company operates in a single operating segment: the development, marketing, and sale of industrial and enterprise IoT products and services. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the U.S, Canada and the Rest of the World. The U.S contribute the vast majority of total revenue.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.